Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) – NICE technology appraisal guidance [TA353]

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer because no evidence submission was received from Roche Products for the technology. Related

The Birthplace in England national prospective cohort study: further analyses to enhance policy and service delivery decision-making for planned place of birth – Health Services and Delivery Research Volume: 3 Issue: 36

Evidence from the Birthplace in England Research Programme supported a policy of offering ‘low risk’ women a choice of birth setting, but a number of unanswered questions remained. This project aimed to provide further evidence to support the development and delivery